

DAFTAR PUSTAKA

1. Elsegaie D, El-Nabarawi MA, Mahmoud HA, Teaima M, Louis D. A Comparative Study on Cyclodextrin Derivatives in Improving Oral Bioavailability of Etoricoxib as a Model Drug: Formulation and Evaluation of Solid Dispersion-Based Fast-Dissolving Tablets. *Biomedicines*. 2023;11(9):1–2.
2. Arora M, Choudhary S, Singh PK, Sapra B, Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review. *Life Sci*. 2020;251(March):1–3.
3. Pubchem. Etoricoxib. National Center for Biotechnology Information. 2023.
4. Srinivasan S, Elhassan GO, Janakiraman AK, Kayarohanam S, Dey T, Moideen J, et al. Preparation and Characterization of Etoricoxib Ternary Complex for the Enhancement of Solubility. *J Pharm Negat Results*. 2023;14(02):1703–4.
5. Sapkal SB, Adhao VS, Thenge RR, Darakhe RA, Shinde SA, Shrikhande VN. Formulation and characterization of solid dispersions of etoricoxib using natural polymers. *Turkish J Pharm Sci*. 2020;17(1):8–9.
6. Apsari K, Chaerunisa AY. Review Jurnal: Upaya Peningkatan Kelarutan Obat. *Farmaka*. 2020;18(2):56–68.
7. Dani P, Puri V, Bansal AK. Solubility advantage from amorphous etoricoxib solid dispersions. *Drug Dev Ind Pharm*. 2014;40(1):92–101.
8. Tran P, Pyo YC, Kim DH, Lee SE, Kim JK, Park JS. Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. *Pharmaceutics*. 2019;11(3):1–26.
9. Senthilkumar K, Vijaya C. Formulation Development of Mouth Dissolving Film of Etoricoxib for Pain Management. *Adv Pharm*. 2015;2015:1–11.
10. Chaudhary VB, Pharmacy SS. Cyclodextrin Inclusion Complex To Enhance Solubility of Poorly Water Soluble Drugs: a Review. *Int J Pharm Sci Res*. 2013;4(1):68–76.
11. Amalia NI. pembentukan dan Karakterisasi Multikomponen Kristal Etoricoxib-Asam Nikotinat dengan Metode Liquid Assisted Grinding. *Univeristas Andalas*; 2023.
12. Karagianni A, Kachrimanis K, Nikolakakis I. Co-amorphous solid dispersions for solubility and absorption improvement of drugs: Composition, preparation, characterization and formulations for oral delivery. *Pharmaceutics*. 2018;10(3):1–26.
13. Lodagekar A, Chavan RB, Mannava MKC, Yadav B, Chella N, Nangia AK, et al. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation. *Eur J Pharm Sci*. 2019;139:1–27.
14. Mizoguchi R, Waraya H, Hirakura Y. Application of Co-Amorphous Technology for Improving the Physicochemical Properties of Amorphous Formulations. *Mol Pharm*. 2019;16(5):2142–52.
15. Chavan RB, Thipparaboina R, Kumar D, Shastri NR. Co amorphous systems: A product development perspective. *Int J Pharm*. 2016;515(1–2):403–15.

16. PubChem. 2023.
17. Hirakawa Y, Ueda H, Takata Y, Minamihata K, Wakabayashi R, Kamiya N, et al. Co-amorphous formation of piroxicam-citric acid to generate supersaturation and improve skin permeation. *Eur J Pharm Sci.* 2021;158:1–22.
18. Han J, Wei Y, Lu Y, Wang R, Zhang J, Gao Y, et al. Co-amorphous systems for the delivery of poorly water-soluble drugs: Recent advances and an update. *Expert Opin Drug Deliv.* 2020;0(0).
19. Thayyil AR, Juturu T, Nayak S, Kamath S. Pharmaceutical Co-crystallization: Regulatory aspects, design, characterization, and applications. *Adv Pharm Bull.* 2020;10(2):205–7.
20. Karagianni A, Malamataris M, Kachrimanis K. Pharmaceutical cocrystals: New solid phase modification approaches for the formulation of APIs. *Pharmaceutics.* 2018;10(1):21–4.
21. Nurul Batrisyia R, Kumar Janakiraman A, Chiau Ming L, Helal Uddin A, Islam Sarker Z, Kai Bin L. A Review On The Solubility Enhancement Technique For Pharmaceutical Formulations. *Volatiles Essent Oils.* 2021;8(4):3976–9.
22. Abdul-Rahman MM, Jawad FJ. Enhancement of aqueous solubility and dissolution rate of etoricoxib by solid dispersion technique. *Iraqi J Pharm Sci.* 2020;29(1):76–7.
23. Wanga Y, Wanga L, Zhang F, Na Wanga, Gao Y, Xiaoa Y, et al. Structure analysis and insight into hydrogen bond and van der waals interactions of etoricoxib cocrystals and cocrystal solvate. *J Mol Struct.* 2022;1258:1–2.
24. Li D, Wang T, Liang L, Qiao H, Chang W, Gao ZY, et al. Pharmacokinetics and bioequivalence of rivaroxaban in healthy volunteers. *Chinese J New Drugs.* 2021;30(15):1401–6.
25. Tjandrawinata RR, Setiawati A, Nofiarny D, Susanto LW, Setiawati E. Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib. *Clin Pharmacol Adv Appl.* 2018;10:43–5.
26. Akhil MB, Velayudhankutty S, Haribabu Y, Mathew S, Nihila K. Review on Analytical Techniques for the Estimation of Pregabalin and Etoricoxib in Combined Dosage Form. *J Pharm Sci Res.* 2021;13(8):457–8.
27. Prajapati M, Yamgar DB, Desale MN, Fegade B. A Review on Various Analytical Methodologies for Etoricoxib. *Adv J Grad Res.* 2021;11(1):61–3.
28. Kale DP, Ugale B, Nagaraja CM, Dubey G, Bharatam P V., Bansal AK. Molecular basis of water sorption behavior of rivaroxaban-malonic acid cocrystal. *Mol Pharm.* 2019;16(7):2980–4.
29. Wu W, Wang Y, Löbmann K, Grohgan H, Rades T. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems. *Mol Pharm.* 2019;16(3):1294–304.
30. Fael H, Demirel AL. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior. *Int J Pharm.* 2020;581(March):1–10.
31. Jensen KT, Blaabjerg LI, Lenz E, Bohr A, Grohgan H, Kleinebudde P, et al. Preparation and characterization of spray-dried co-amorphous drug-

- amino acid salts. *J Pharm Pharmacol*. 2016;68(5):615–24.
32. Nair A, Varma R, Gourishetti K, Bhat K, Dengale S. Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin. *J Pharm Innov*. 2020;15(3):365–79.
 33. Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. *Acta Pharm Sin B*. 2019;9(1):19–35.
 34. Sopyan I, N FD, HS I, KY N, TW O, Sarah D. a Review on Solids State of Characterization Method in Pharmaceuticals. *Int Res J Pharm*. 2019;10(1):6–10.
 35. Shi Q, Moinuddin SM, Cai T. Advances in coamorphous drug delivery systems. *Acta Pharm Sin B*. 2019;9(1):19–35.
 36. Martínez LM, Cruz-Angeles J, Vázquez-Dávila M, Martínez E, Cabada P, Navarrete-Bernal C, et al. Mechanical Activation by Ball Milling as a Strategy to Prepare Highly Soluble Pharmaceutical Formulations in the Form of Co-Amorphous, Co-Crystals, or Polymorphs. *Pharmaceutics*. 2022;14(10):2–42.
 37. Soyata A, Kenti K, Sutoro M, Sagita N. Impact of Preparation Method in Co-Amorphous System. *Sci Pharm*. 2022;1(1):41–9.
 38. Saberi A, Kouhjani M, Yari D, Jahani A, Asare-Addo K, Kamali H, et al. Development, recent advances, and updates in binary, ternary co-amorphous systems, and ternary solid dispersions. *J Drug Deliv Sci Technol*. 2023;86(June):104746.
 39. Park H, Jin Seo H, Hong S hyeon, Ha ES, Lee S, Kim JS, et al. Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods. *Int J Pharm*. 2020;581(March):1–11.
 40. J W LQ. *Pharmaceutical Salts and Co-crystals*. 2012. 214–216 p.
 41. Farongsarn D. Theoretical Aspects of Differential Scanning Calorimetry as a Tool for the Studies of Equilibrium Thermodynamics in Pharmaceutical Solid Phase Transitions. *AAPS PharmSciTech*. 2016;17(3):572–4.
 42. Skotnicki M, Jadach B, Skotnicka A, Milanowski B, Tajber L, Pyda M, et al. Physicochemical characterization of a co-amorphous atorvastatin-irbesartan system with a potential application in fixed-dose combination therapy. *Pharmaceutics*. 2021;13(1):1–20.
 43. Shelke R, Velagacherla V, Nayak UY. Recent advances in dual-drug co-amorphous systems. *Drug Discov Today*. 2023;1–13.
 44. Aitipamula S, Vangala VR. X-Ray Crystallography and its Role in Understanding the Physicochemical Properties of Pharmaceutical Cocrystals. *J Indian Inst Sci*. 2017;97(2):227–30.
 45. Ainurofiq A, Mauludin R, Mudhakir D, Soewandhi SN. A novel desloratadine-benzoic acid co-amorphous solid: Preparation, characterization, and stability evaluation. *Pharmaceutics*. 2018;10(3).
 46. Patole T, Deshpande A. Co-Crystallization-a Technique for Solubility Enhancement. *Int J Pharm Sci Res*. 2014;5(9):3566–74.
 47. Chauhan A. Powder XRD Technique and its Applications in Science and Technology. *J Anal Bioanal Tech*. 2014;5(6):1–3.

48. Pekar KB, Lefton JB, McConville CA, Burlison J, Sethio D, Kraka E, et al. Mechano-synthesis of a Coamorphous Formulation of Creatine with Citric Acid and Humidity-Mediated Transformation into a Cocrystal. *Cryst Growth Des.* 2021;21(2):1297–306.
49. Dutta A. *Fourier Transform Infrared Spectroscopy. Vol. 2, Spectroscopic Methods for Nanomaterials Characterization.* Elsevier Inc.; 2017. 73–93 p.
50. Lin SY. Simultaneous screening and detection of pharmaceutical co-crystals by the one-step DSC–FTIR microspectroscopic technique. *Drug Discov Today.* 2017;22(4):716–9.
51. Healy AM, Worku ZA, Kumar D, Madi AM. Pharmaceutical solvates, hydrates and amorphous forms: A special emphasis on cocrystals. *Adv Drug Deliv Rev.* 2017;117:39–40.
52. Liu J, Rades T, Grohganz H. The influence of moisture on the storage stability of co-amorphous systems. *Int J Pharm.* 2021;605(June):120802.
53. Chettri A, Subba A, Singh GP, Bag PP. Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy. *J Pharm Pharmacol.* 2023;(November):6.
54. Depkes RI. *Farmakope Indonesia edisi VI.* Departemen Kesehatan Republik Indonesia. 2020.
55. Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: Current understanding and recent trends. *Drug Dev Ind Pharm.* 2015;41(6):875–82.
56. Shaikh R, Singh R, Walker GM, Croker DM. Pharmaceutical Cocrystal Drug Products: An Outlook on Product Development. *Trends Pharmacol Sci.* 2018;39(12):1033–5.
57. Setyawan D, Permata SA, Zainul A, Dwi Lestari MLA. Improvement in vitro dissolution rate of quercetin using cocrystallization of quercetin-malonic acid. *Indones J Chem.* 2018;18(3):531–6.
58. Zaini E, Afriyani, Fitriani L, Ismed F, Horikawa A, Uekusa H. Improved solubility and dissolution rates in novel multicomponent crystals of piperine with succinic acid. *Sci Pharm.* 2020;88(2):1–13.
59. Susanti M dan D. *Kromatografi Cair Kinerja Tinggi.* Padang: LPTIK Universitas Andalas; 2017.
60. Sabir AM, Moloy M, Bhasin PS. Hplc Method Development and Validation: a Review. *Int Res J Pharm.* 2016;4(4):39–42.
61. Rochman A. *Analisis Farmasi dengan Kromatografi Cair [Internet].* Yogyakarta: Gadjah Mada University Press; 2020.
62. Rashmi D. A Review on Analytical method Development and Validation. *J Drug Deliv Ther.* 2018;8(6):124–8.
63. Sugihartini N, Fudholi A, Pramono S, Sismindari. Validation Method of Quantitative Analysis of Epigallocatechin Gallat By Thin Layer Chromatography. *J Ilm Kefarmasian.* 2012;4(2):81–7.
64. F WG of I of H. *Indian Pharmacopoeia 2022. Vol. II. The Indian Pharmacopoeia Commission Ghaziabad;* 2022.
65. Nayak AK, Panigrahi PP. Solubility Enhancement of Etoricoxib by Cosolvency Approach. 2012;2012.
66. Arif Z. Pembentukan Ko-amorf Tenoksikam dan Meglumine dengan Metode Solvent Drop Grinding Serta Karakterisasi Sifat Fisiko Kimia. Universitas

- Andalas; 2020.
67. Rohman A. Validasi dan Penjaminan Mutu Metode Analisis Kimia. Yogyakarta: Gadjah Mada University Press; 2014.
 68. Welfare F. Indian Pharmacopoeia Vol. II. Vol. II. The Indian Pharmacopoeia Commission Ghaziabad; 2018. 480–481 p.
 69. D'Angelo A, Edgar B, Hurt AP, Antonijević MD. Physico-chemical characterisation of three-component co-amorphous systems generated by a melt-quench method. *J Therm Anal Calorim.* 2018;134(1):381–90.
 70. Silverstein RM, Bassler G, Morrill C. Identificación espectrométrica de compuestos orgánicos. *Química Orgânica: Compostos orgânicos - Espectrometria.* 1980. 353 p.
 71. Wicaksono Y, Rosidi VA, Saragih SY, Fauziah LS, Setyawan D. Preparation of spray dried coamorphous solids to improve the solubility and dissolution rate of atorvastatin calcium. *J Teknol.* 2021;83(2):77–83.
 72. Rosydiati. Karakterisasi puncak kromatogram dalam High Performance Liquid Chromatography (HPLC) terhadap perbedaan fase gerak, laju alir, dan penambahan asam dalam analisis Indole Acetic Acid (IAA). *Kandaga.* 2019;1(2):65–73.
 73. Bazzo GC, Pezzini BR, Stulzer HK. Eutectic mixtures as an approach to enhance solubility, dissolution rate and oral bioavailability of poorly water-soluble drugs. *Int J Pharm.* 2020;588(May):119741.
 74. Wang J, Chang R, Zhao Y, Zhang J, Zhang T, Fu Q, et al. Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability. *AAPS PharmSciTech.* 2017;18(7):2541–50.

